OBJECTIVES: We compared the ability of molecular biomarkers for Alzheimer disease (AD), including amyloid imaging and CSF biomarkers (Aβ42, tau, ptau181, tau/Aβ42, ptau181/Aβ42), to predict time to incident cognitive impairment among cognitively normal adults aged 45 to 88 years and followed for up to 7.5 years. METHODS: Longitudinal data from Knight Alzheimer's Disease Research Center participants (N = 201) followed for a mean of 3.70 years (SD = 1.46 years) were used. Participants with amyloid imaging and CSF collection within 1 year of a clinical assessment indicating normal cognition were eligible. Cox proportional hazards models tested whether the individual biomarkers were related to time to incident cognitive impairment. "Expanded" models were developed using the biomarkers and participant demographic variables. The predictive values of the models were compared. RESULTS: Abnormal levels of all biomarkers were associated with faster time to cognitive impairment, and some participants with abnormal biomarker levels remained cognitively normal for up to 6.6 years. No differences in predictive value were found between the individual biomarkers (p > 0.074), nor did we find differences between the expanded biomarker models (p > 0.312). Each expanded model better predicted incident cognitive impairment than the model containing the biomarker alone (p < 0.005). CONCLUSIONS: Our results indicate that all AD biomarkers studied here predicted incident cognitive impairment, and support the hypothesis that biomarkers signal underlying AD pathology at least several years before the appearance of dementia symptoms.
OBJECTIVES: We compared the ability of molecular biomarkers for Alzheimer disease (AD), including amyloid imaging and CSF biomarkers (Aβ42, tau, ptau181, tau/Aβ42, ptau181/Aβ42), to predict time to incident cognitive impairment among cognitively normal adults aged 45 to 88 years and followed for up to 7.5 years. METHODS: Longitudinal data from Knight Alzheimer's Disease Research Center participants (N = 201) followed for a mean of 3.70 years (SD = 1.46 years) were used. Participants with amyloid imaging and CSF collection within 1 year of a clinical assessment indicating normal cognition were eligible. Cox proportional hazards models tested whether the individual biomarkers were related to time to incident cognitive impairment. "Expanded" models were developed using the biomarkers and participant demographic variables. The predictive values of the models were compared. RESULTS: Abnormal levels of all biomarkers were associated with faster time to cognitive impairment, and some participants with abnormal biomarker levels remained cognitively normal for up to 6.6 years. No differences in predictive value were found between the individual biomarkers (p > 0.074), nor did we find differences between the expanded biomarker models (p > 0.312). Each expanded model better predicted incident cognitive impairment than the model containing the biomarker alone (p < 0.005). CONCLUSIONS: Our results indicate that all AD biomarkers studied here predicted incident cognitive impairment, and support the hypothesis that biomarkers signal underlying AD pathology at least several years before the appearance of dementia symptoms.
Authors: M A Mintun; G N Larossa; Y I Sheline; C S Dence; S Y Lee; R H Mach; W E Klunk; C A Mathis; S T DeKosky; J C Morris Journal: Neurology Date: 2006-08-08 Impact factor: 9.910
Authors: Anne M Fagan; Mark A Mintun; Robert H Mach; Sang-Yoon Lee; Carmen S Dence; Aarti R Shah; Gina N LaRossa; Michael L Spinner; William E Klunk; Chester A Mathis; Steven T DeKosky; John C Morris; David M Holtzman Journal: Ann Neurol Date: 2006-03 Impact factor: 10.422
Authors: Anne M Fagan; Denise Head; Aarti R Shah; Daniel Marcus; Mark Mintun; John C Morris; David M Holtzman Journal: Ann Neurol Date: 2009-02 Impact factor: 10.422
Authors: Randy L Buckner; Abraham Z Snyder; Benjamin J Shannon; Gina LaRossa; Rimmon Sachs; Anthony F Fotenos; Yvette I Sheline; William E Klunk; Chester A Mathis; John C Morris; Mark A Mintun Journal: J Neurosci Date: 2005-08-24 Impact factor: 6.167
Authors: Andrew J Aschenbrenner; David A Balota; Anne M Fagan; Janet M Duchek; Tammie L S Benzinger; John C Morris Journal: J Int Neuropsychol Soc Date: 2015-09 Impact factor: 2.892
Authors: Jason Hassenstab; Sarah E Monsell; Charles Mock; Catherine M Roe; Nigel J Cairns; John C Morris; Walter Kukull Journal: J Neuropathol Exp Neurol Date: 2015-11 Impact factor: 3.685
Authors: Clifford R Jack; David S Knopman; Gaël Chételat; Dennis Dickson; Anne M Fagan; Giovanni B Frisoni; William Jagust; Elizabeth C Mormino; Ronald C Petersen; Reisa A Sperling; Wiesje M van der Flier; Victor L Villemagne; Pieter J Visser; Stephanie J B Vos Journal: Nat Rev Neurol Date: 2016-01-18 Impact factor: 42.937
Authors: Suzanne E Schindler; Courtney L Sutphen; Charlotte Teunissen; Lena M McCue; John C Morris; David M Holtzman; Sandra D Mulder; Philip Scheltens; Chengjie Xiong; Anne M Fagan Journal: Alzheimers Dement Date: 2017-07-12 Impact factor: 21.566
Authors: Murat Bilgel; Rebecca L Koscik; Yang An; Jerry L Prince; Susan M Resnick; Sterling C Johnson; Bruno M Jedynak Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Bliss Elizabeth O'Bryhim; Rajendra S Apte; Nathan Kung; Dean Coble; Gregory P Van Stavern Journal: JAMA Ophthalmol Date: 2018-11-01 Impact factor: 7.389